Sage Targets June Launch as FDA Approves Postpartum Drug

The video discusses the approval of a new drug for postpartum depression, highlighting its significance as a major medical milestone. It covers drug pricing, emphasizing the importance of access and positive responses from payers. Sales forecasts are discussed, with expectations for a significant launch impact. Future plans include new drug developments and a focus on long-term business strategy. The financial position is strong, with recent fundraising ensuring stability and continued investment in R&D.

What are the expected sales figures for the new drug in 2019?

What is the long-term vision for Sage in terms of drug development?